Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Leukemia 31Leukemia, Promyelocytic, Acute 27Multiple Myeloma 17Leukemia, Myeloid, Acute 16Neoplasms, Plasma Cell 12Myelodysplastic Syndromes 12Leukemia, Myelomonocytic, Chronic 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Anemia, Refractory, with Excess of Blasts 7Lymphoma 6Leukemia, Monocytic, Acute 6Leukemia, Lymphocytic, Chronic, B-Cell 6Blast Crisis 6Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma, Follicular 5Leukemia, Myelomonocytic, Acute 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Erythroblastic, Acute 5Burkitt Lymphoma 5Recurrence 4Myeloproliferative Disorders 4Myelodysplastic-Myeloproliferative Diseases 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Immunoblastic 4Lymphoma, Large B-Cell, Diffuse 4Leukemia, Myeloid, Chronic-Phase 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4Central Nervous System Neoplasms 4

Interventions

Sorafenib 3pazopanib 2Sunitinib 2verubulin 1trifluridine tipiracil drug combination 1irinotecan sucrosofate 1eribulin 1Valproic Acid 1Temozolomide 1Sirolimus 1Irinotecan 1Interleukin-27 1Hydralazine 1Erlotinib Hydrochloride 1Azurin 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Refractory Solid Tumors × Arsenic Trioxide × Clear all
NCT04869475 2021-05-13

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Ruijin Hospital

Phase 2 Unknown
20 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡